Results above point out that STOML2 interacts with PHB, promotes CRC proliferation by regulating MAPK pathway; disrupting STOML2-PHB interaction and subsequently activated MAPK signaling pathway is proved to be promising therapeutic strategy for STOML2-overexpressed CRC (Fig. 6O). The gene discussed is PHB1; the disease is colorectal carcinoma.